The silymarin treatment improved liver function by decreasing the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), superoxide dismutase/catalase (SOD/CAT), thiobarbituric acid reactive substances (TBARSs), hypertriglyceridemia, and hypercholesterolemia. The gene discussed is CAT; the disease is Hypercholesterolemia.